Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease
- PMID: 24445704
- PMCID: PMC4096316
- DOI: 10.7326/L14-5001-7
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease
Conflict of interest statement
Comment on
-
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.Ann Intern Med. 2013 Sep 17;159(6):382-9. doi: 10.7326/0003-4819-159-6-201309170-00004. Ann Intern Med. 2013. PMID: 24042366 Free PMC article.
-
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.Ann Intern Med. 2014 Jan 21;160(2):141-2. doi: 10.7326/L14-5001-5. Ann Intern Med. 2014. PMID: 24592503 No abstract available.
-
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.Ann Intern Med. 2014 Jan 21;160(2):142-3. doi: 10.7326/L14-5001-6. Ann Intern Med. 2014. PMID: 24592504 No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources